| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000031545 |
| Receipt No. | R000036020 |
| Official scientific title of the study | Visceral fat-reducing effect of food containing the milk-derived ingredient |
| Date of disclosure of the study information | 2018/03/02 |
| Last modified on | 2019/03/04 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Visceral fat-reducing effect of food containing the milk-derived ingredient | |
| Title of the study (Brief title) | Visceral fat-reducing effect of food containing the milk-derived ingredient | |
| Region |
|
|
| Condition | ||
| Condition | No (healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To examine the visceral fat-reducing effect of food containing the milk-derived ingredient |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Visceral fat area |
| Key secondary outcomes | Subcutaneous fat area, Total fat area, Waist circumference, Hip circumference, Body weight, BMI |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Food containing the milk-derived ingredient, 12 weeks | |
| Interventions/Control_2 | Food non-containing the milk-derived ingredient, 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Japanese males and females aged 20 to 64 years old at the time of acquiring consent.
(2) Subjects whose BMI are 23 to 29.9 at the screening test. (3) Subjects with visceral fat areas of more than 70 cm2 at the screening test. (4) Subjects who provided written informed consent. |
|||
| Key exclusion criteria | (1) Subjects with the metabolic syndrome.
(2) Subjects who have taken medication or surgery due to serious illness or injury within one month before the start of the study. (3) Subjects who have serious diseases in the heart, liver, kidney or digestive organs in the present or past. (4) Subjects who take a medicine for hyperglycemia, hyperlipidemia or hypertension. (5) Subjects who regularly use drugs or functional foods affecting the study. (6) Subjects who are pregnant or lactating. (7) Heavy drinkers or heavy smokers. (8) Subjects with milk allergy. (9) Subjects who are judged as unsuitable for the study by the investigator for the other reason. |
|||
| Target sample size | 140 | |||
| Research contact person | |
| Name of lead principal investigator | Ikuo Fukuhara |
| Organization | Fukuhara Clinic |
| Division name | Director |
| Address | 3-1-15, Shima-matsuhigashi machi, Eniwa-shi, Hokkaido, Japan |
| TEL | 0123-36-8029 |
| i-feniwa@gray.plala.or.jp | |
| Public contact | |
| Name of contact person | Shimpei Tomita |
| Organization | New drug research center, Inc. |
| Division name | Clinical Research Dept. |
| Address | 452-1, Toiso, Eniwa-shi, Hokkaido, Japan |
| TEL | 0123-34-0412 |
| Homepage URL | |
| s-tomita@ndrcenter.co.jp | |
| Sponsor | |
| Institute | New drug research center, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | LION Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 福原医院(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036020 |